<DOC>
	<DOC>NCT01213446</DOC>
	<brief_summary>This is an open-label study to investigate the pharmacokinetics (PK), efficacy, and safety of a von Willebrand Factor/Factor VIII (VWF/FVIII), Biostate, in children with Von Willebrand disease (VWD) in whom treatment with a VWF product is required for prophylactic therapy, haemostatic control during surgery, or control of a non-surgical, spontaneous, or traumatic bleeding event.</brief_summary>
	<brief_title>Study of BiostateÂ® in Children With Von Willebrand Disease</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>Male and female subjects between 0 and &lt;12 years of age Diagnosed with VWD Type 1, 2A, or 3 Desmopressin acetate (DDAVP) treatment is ineffective, contraindicated, or not available for subject von Willebrand factor: ristocetin cofactor (VWF:RCo) is &lt;20% at screening or the subject has a history of VWF:RCo &lt;10% Evidence of vaccination against hepatitis A and B or presence of antibodies against hepatitis A and B due to either a previous infection or prior immunization Written informed consent given Active bleeding immediately prior to initial PK period Received treatment with DDAVP or a VWF concentrate product for their VWD in the 5 days prior to their first study treatment Have received aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) within 7 days of commencing the PK period. Known history or suspicion of having VWF or FVIII inhibitors Acute or chronic medical condition, other than VWD, which may affect the conduct of the study Known or suspected hypersensitivity or previous evidence of severe side effects to other FVIII/VWF concentrates Participation in a clinical study or use of an investigational compound in another study in the 3 months preceding study start Unwillingness and/or inability to comply with the study requirements</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Von Willebrand Disease</keyword>
</DOC>